American Society of Hematology Annual Meeting

Darzalex Regimen May Improve MRD Responses in Multiple Myeloma

December 21st 2024, 3:00pm

Article

Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.

What is Follicular Lymphoma and Why Are Better Treatments Needed?

December 19th 2024, 2:00pm

Video

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable.

Imbruvica-Venetoclax Shows Promise in Managing CLL

December 18th 2024, 2:00pm

Article

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.

Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey

December 17th 2024, 4:00pm

Article

Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.

Tecartus After Outpatient Lymphodepletion Safe, Effective in B-ALL and MCL

December 16th 2024, 4:00pm

Article

Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.

Survival Outcomes Not Improved With Autologous Stem Cell Transplant in MCL

December 11th 2024, 1:11am

Article

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma

December 10th 2024, 8:48pm

Article

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.

Uproleselan Fails to Improve Survival in AML, Although Some Subgroups May Benefit

December 10th 2024, 4:00pm

Article

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary refractory patients.

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

December 10th 2024, 2:05pm

Article

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers

December 9th 2024, 11:00pm

Article

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.